NCT03482024View on ClinicalTrials.gov

A Study of Tirzepatide (LY3298176) in Participants With Impaired Kidney Function

PHASE1CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

March 30, 2018

Primary Completion Date

August 19, 2019

Study Completion Date

August 19, 2019

Conditions
Renal InsufficiencyEnd Stage Renal Disease
Interventions
DRUG

Tirzepatide

Administered SC.

Trial Locations (4)

27265

High Point Clinical Trials Center, High Point

32809

Orlando Clinical Research Center, Orlando

33014

Clinical Pharmacology of Miami, Miami

92780

Orange County Research Center, Tustin

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT03482024 - A Study of Tirzepatide (LY3298176) in Participants With Impaired Kidney Function | Biotech Hunter | Biotech Hunter